Literature DB >> 11507642

Antibodies inhibit prion propagation and clear cell cultures of prion infectivity.

D Peretz1, R A Williamson, K Kaneko, J Vergara, E Leclerc, G Schmitt-Ulms, I R Mehlhorn, G Legname, M R Wormald, P M Rudd, R A Dwek, D R Burton, S B Prusiner.   

Abstract

Prions are the transmissible pathogenic agents responsible for diseases such as scrapie and bovine spongiform encephalopathy. In the favoured model of prion replication, direct interaction between the pathogenic prion protein (PrPSc) template and endogenous cellular prion protein (PrPC) is proposed to drive the formation of nascent infectious prions. Reagents specifically binding either prion-protein conformer may interrupt prion production by inhibiting this interaction. We examined the ability of several recombinant antibody antigen-binding fragments (Fabs) to inhibit prion propagation in cultured mouse neuroblastoma cells (ScN2a) infected with PrPSc. Here we show that antibodies binding cell-surface PrPC inhibit PrPSc formation in a dose-dependent manner. In cells treated with the most potent antibody, Fab D18, prion replication is abolished and pre-existing PrPSc is rapidly cleared, suggesting that this antibody may cure established infection. The potent activity of Fab D18 is associated with its ability to better recognize the total population of PrPC molecules on the cell surface, and with the location of its epitope on PrPC. Our observations support the use of antibodies in the prevention and treatment of prion diseases and identify a region of PrPC for drug targeting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507642     DOI: 10.1038/35089090

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  133 in total

1.  Abrogation of complex glycosylation by swainsonine results in strain- and cell-specific inhibition of prion replication.

Authors:  Shawn Browning; Christopher A Baker; Emery Smith; Sukhvir P Mahal; Maria E Herva; Cheryl A Demczyk; Jiali Li; Charles Weissmann
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

2.  Effects of a brain-engraftable microglial cell line expressing anti-prion scFv antibodies on survival times of mice infected with scrapie prions.

Authors:  Koji Fujita; Yoshitaka Yamaguchi; Tsuyoshi Mori; Naomi Muramatsu; Takahito Miyamoto; Masashi Yano; Hironori Miyata; Akira Ootsuyama; Makoto Sawada; Haruo Matsuda; Ryuji Kaji; Suehiro Sakaguchi
Journal:  Cell Mol Neurobiol       Date:  2011-04-23       Impact factor: 5.046

3.  vCJD: the epidemic that never was. New variant Creutzfeldt-Jakob disease: the critique that never was.

Authors:  R G Will; R S G Knight; H J T Ward; J W Ironside
Journal:  BMJ       Date:  2002-07-13

Review 4.  Back to the future: antibody-based strategies for the treatment of infectious diseases.

Authors:  H Barbaros Oral; Cüneyt Ozakin; Cezmi A Akdiş
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

5.  Sphingosine kinase-dependent migration of immature dendritic cells in response to neurotoxic prion protein fragment.

Authors:  Nicole C Kaneider; Arthur Kaser; Stefan Dunzendorfer; Herbert Tilg; Christian J Wiedermann
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

6.  Pauling and Corey's alpha-pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease.

Authors:  Roger S Armen; Mari L DeMarco; Darwin O V Alonso; Valerie Daggett
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-27       Impact factor: 11.205

7.  From conversion to aggregation: protofibril formation of the prion protein.

Authors:  Mari L DeMarco; Valerie Daggett
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

8.  One O-linked sugar can affect the coil-to-beta structural transition of the prion peptide.

Authors:  Pei-Yeh Chen; Chun-Cheng Lin; Yin-Ting Chang; Su-Ching Lin; Sunney I Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

Review 9.  Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development.

Authors:  Joanna L Jankowsky; Alena Savonenko; Gabriele Schilling; Jiou Wang; Guilian Xu; David R Borchelt
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

10.  Testing the possibility to protect bovine PrPC transgenic Swiss mice against bovine PrPSc infection by DNA vaccination using recombinant plasmid vectors harboring and expressing the complete or partial cDNA sequences of bovine PrPC.

Authors:  Sandra Müller; Roland Kehm; Michaela Handermann; Nurith J Jakob; Udo Bahr; Björn Schröder; Gholamreza Darai
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.